Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

Recruiting

• Conditions: Pulmonary Artery Sarcoma

• Registration Number: NCT06165718
• Lead Sponsor: China-Japan Friendship Hospital

Brief Summary

This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Detailed Description

This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Study Timeline

• Study Start: 2022-12-31
• Status Verified: 2023-12
• Study First Submitted: 2023-12-04
• Study First Submitted QC: 2023-12-04
• Study First Posted: 2023-12-11
• Last Update Submitted: 2023-12-11
• Last Update Posted: 2023-12-15
• Primary Completion: 2024-12-31
• Study Completion: 2025-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Computed tomography pulmonary angiography indicated that there were intraluminal defects
• Malignant histopathology was sarcoma
• Informed consent form was signed

Exclusion Criteria

• Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma
• Expected inability to complete follow-up

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival	36 months	Time to death or disease progression

Secondary Outcome Measures

Name	Time	Method
Overall survival	36 months	Time to death
Postoperative survival	36 months	Time from surgery to death

Trial Locations

Locations (1)

China-Japan Friendship Hospital; 🇨🇳 Beijing, Beijing, China